EXPLAINED: State Regulation of Medication Abortion Lecture

Dr. Ushma Upadhyay, of the University of California San Francisco, explains the most up-to-date research on the state regulation of medication abortion.

Download the EXPLAINED: State Regulation of Medication Abortion Facilitator Guide with Quiz.

Don’t have time for the full lecture? Watch the short series and view the infographic.

The following links provided the research used in this video:

Boonstra HD. Medication Abortion Restrictions Burden Women and Providers—and Threaten U.S. Trend Toward Very Early Abortion. Guttmacher 2013.
Chong E, Frye LJ, Castle J, Dean G, Kuehl L, Winikoff B. A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S. 2015;92(3):215-219.
Clinical Practice Handbook for Safe Abortion. World Health Organization; 2014.
Greene MF, Drazen JM. A New Label for Mifepristone. N Eng J Med. 2016;374(23):2281-2282.
Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011;118(2 Pt 1):296-303.
Grossman DA, Grindlay K, Buchacker T, Potter JE, Schmertmann CP. Changes in service delivery patterns after introduction of telemedicine provision of medical abortion in Iowa. Am J Public Health. 2013;103(1):73-78.
Mitka M. Some men who take Viagra die–why? 2000;283(5):590, 593.
NAF Protocol for Mifepristone/Misoprostol in Early Abortion in the U.S. National Abortion Federation; 2010.
Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.
Postmarket Drug Safety Information for Patients and Providers: Mifeprex (mifepristone) Information.S. Food and Drug Administration; 2016.
Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676-692.
Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med. 1998;338(18):1241-1247.
Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol. 2015;125(1):175-183.
Upadhyay UD, Johns NE, Combellick SL, Kohn JE, Keder LM, Roberts SC. Comparison of Outcomes before and after Ohio’s Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study. PLoS Med. 2016;13(8):e1002110.
Winikoff B, Westhoff C. Fifteen years: looking back and looking forward. 2015;92(3):177-178.

EXPLAINED: State Regulation of Medication Abortion

Dr. Ushma Upadhyay, of the University of California San Francisco, explains the most up-to-date research on the state regulation of medication abortion.

For more information, watch the extended lecture version and download the video companion materials.

The following links provided the research used in this video:

Boonstra HD. Medication Abortion Restrictions Burden Women and Providers—and Threaten U.S. Trend Toward Very Early Abortion. Guttmacher 2013.
Chong E, Frye LJ, Castle J, Dean G, Kuehl L, Winikoff B. A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S. 2015;92(3):215-219.
Clinical Practice Handbook for Safe Abortion. World Health Organization; 2014.
Greene MF, Drazen JM. A New Label for Mifepristone. N Eng J Med. 2016;374(23):2281-2282.
Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011;118(2 Pt 1):296-303.
Grossman DA, Grindlay K, Buchacker T, Potter JE, Schmertmann CP. Changes in service delivery patterns after introduction of telemedicine provision of medical abortion in Iowa. Am J Public Health. 2013;103(1):73-78.
Mitka M. Some men who take Viagra die–why? 2000;283(5):590, 593.
NAF Protocol for Mifepristone/Misoprostol in Early Abortion in the U.S. National Abortion Federation; 2010.
Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.
Postmarket Drug Safety Information for Patients and Providers: Mifeprex (mifepristone) Information.S. Food and Drug Administration; 2016.
Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676-692.
Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med. 1998;338(18):1241-1247.
Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol. 2015;125(1):175-183.
Upadhyay UD, Johns NE, Combellick SL, Kohn JE, Keder LM, Roberts SC. Comparison of Outcomes before and after Ohio’s Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study. PLoS Med. 2016;13(8):e1002110.
Winikoff B, Westhoff C. Fifteen years: looking back and looking forward. 2015;92(3):177-178.

EXPLAINED: Who Can Safely Provide Abortion? Lecture

Dr. Monica McLemore, of the University of California San Francisco, explains the most up-to-date research on who can safely provide abortions.

Download the EXPLAINED: Who Can Safely Provide Abortion? Facilitator Guide with Quiz.

Don’t have time for the full lecture? Watch the short series version and view the infographic.

The following links provided the research used in this video:

Aztlan-James EA, McLemore M, Taylor D. Multiple Unintended Pregnancies in U.S. Women: A Systematic Review. Womens Health Issues.
Freedman L, Battistelli MF, Gerdts C, McLemore M. Radical or routine? Nurse practitioners, nurse-midwives, and physician assistants as abortion providers. Reprod Health Matters. 2015;23(45):90-92.
McLemore M, Levi A. Nurses and care of women seeking abortions, 1971 to 2011. J Obstet Gynecol Neonatal Nurs. 2011;40(6):672-677.
McLemore MR, Desai S, Freedman L, James EA, Taylor D. Women know best–findings from a thematic analysis of 5,214 surveys of abortion care experience. Womens Health Issues. 2014;24(6):594-599.
McLemore MR, Kools S, Levi AJ. Calculus formation: nurses’ decision-making in abortion-related care. Res Nurs Health. 2015;38(3):222-231.
Taylor D, Postlethwaite D, Desai S, et al. Multiple determinants of the abortion care experience: from the patient’s perspective. Am J Med Qual. 2013;28(6):510-518.
Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol. 2015;125(1):175-183.
Weitz TA, Taylor D, Upadhyay UD, Desai S, Battistelli M. Research informs abortion care policy change in California. Am J Public Health. 2014;104(10):e3-4.